417 related articles for article (PubMed ID: 33539970)
1. Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
Hellyer JA; Aredo JV; Das M; Ramchandran K; Padda SK; Neal JW; Wakelee HA
J Thorac Oncol; 2021 May; 16(5):868-872. PubMed ID: 33539970
[TBL] [Abstract][Full Text] [Related]
2. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
[TBL] [Abstract][Full Text] [Related]
3. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW; Wakelee HA; Liu Y; Lin SH; Abuali T; Amini A; Nie Y; Patil T; Lobachov A; Bar J; Fitzgerald B; Fujiwara Y; Marron TU; Thummalapalli R; Yu H; Owen DH; Sharp J; Farid S; Rocha P; Arriola E; D'Aiello A; Cheng H; Whitaker R; Parikh K; Ashara Y; Chen L; Sankar K; Harris JP; Nagasaka M; Ayanambakkam A; Velazquez AI; Ragavan M; Lin JJ; Piotrowska Z; Wilgucki M; Reuss J; Luders H; Grohe C; Baena Espinar J; Feiner E; Punekar SR; Gupta S; Leal T; Kwiatkowski DJ; Mak RH; Adib E; Naqash AR; Goldberg SB
J Thorac Oncol; 2024 Jun; 19(6):928-940. PubMed ID: 38278303
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Lobefaro R; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar-Nana F; Ponce S; Dal Maso A; Spotti M; Mielgo-Rubio X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier J; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Planchard D; Mezquita L
Eur J Cancer; 2022 May; 167():142-148. PubMed ID: 35307254
[TBL] [Abstract][Full Text] [Related]
6. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
[TBL] [Abstract][Full Text] [Related]
7. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Kato T; Casarini I; Cobo M; Faivre-Finn C; Hegi-Johnson F; Lu S; Özgüroğlu M; Ramalingam SS
Lung Cancer; 2024 Jan; 187():107414. PubMed ID: 38088015
[TBL] [Abstract][Full Text] [Related]
8. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
Morgensztern D; Govindan R
J Thorac Oncol; 2021 Dec; 16(12):1999-2001. PubMed ID: 34809804
[No Abstract] [Full Text] [Related]
12. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K; Mizugaki H; Yokoo K; Kobayashi M; Kawashima Y; Kimura N; Yokouchi H; Kikuchi H; Sumi T; Kawai Y; Kobashi K; Morita R; Ito K; Kitamura Y; Minemura H; Nakamura K; Aso M; Honjo O; Tanaka H; Takashina T; Tsurumi K; Sugisaka J; Tsukita Y; Konno S; Oizumi S
Cancer Sci; 2024 Apr; 115(4):1273-1282. PubMed ID: 38287788
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL
Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.
Wang CC; Chiu LC; Ju JS; Lin YC; Fang YF; Yang CT; Hsu PC
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696229
[TBL] [Abstract][Full Text] [Related]
15. Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
Aredo JV; Hellyer JA; Neal JW; Wakelee HA
J Thorac Oncol; 2021 Dec; 16(12):1994-1998. PubMed ID: 34809803
[No Abstract] [Full Text] [Related]
16. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
Liu Y; Zhang Z; Rinsurongkawong W; Gay CM; Le X; Ning MS; Lewis J; Rinsurongkawong V; Lee JJ; Roth J; Swisher S; Gandhi S; Lee PP; Gibbons DL; Vaporciyan AA; Heymach JV; Zhang J; Lin SH
JAMA Netw Open; 2022 Jun; 5(6):e2215589. PubMed ID: 35666500
[TBL] [Abstract][Full Text] [Related]
17. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
[TBL] [Abstract][Full Text] [Related]
18. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
Hussain S; Klugarova J; Klugar M
Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
